NUCLEIX
Live / Registered — Registered (as of 26 Nov 2024)
What this means for you
Registered since 26 Nov 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97848574
- Registration number
- 7575478
- Mark type
- Word mark
- Filed
- 21 Mar 2023
- Published for opposition
- 24 Sept 2024
- Registered
- 26 Nov 2024
- Attorney of record
- Jennifer Sheehan Anderson
Goods and services
- Class 001 — Chemicals: Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use
- Class 005 — Pharmaceuticals: Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic assay kits comprised of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD) autoimmune disease and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease in the field of cancer detection or detection, detection of chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; diagnostic reagents for medical purposes
- Class 010 — Medical apparatus: Medical apparatus for medical diagnostic testing in the fields of cancer or chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease
- Class 042 — Scientific and technological services: Pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays
- Class 044 — Medical, beauty and agricultural services: Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease; providing cancer screening services; providing medical screening services for chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease
Owner
- Nucleix Limited, Rehovot, IL
- Nucleix Limited, Rehovot, IL
- Nucleix Limited, Rehovot, IL
Prior registrations
Prosecution history
- 26 Nov 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Nov 2024 — REGISTERED-PRINCIPAL REGISTER
- 24 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Sept 2024 — PUBLISHED FOR OPPOSITION
- 04 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Aug 2024 — ASSIGNED TO LIE
- 04 Mar 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Jan 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Jan 2024 — NON-FINAL ACTION E-MAILED
- 04 Jan 2024 — NON-FINAL ACTION WRITTEN
- 13 Dec 2023 — ASSIGNED TO EXAMINER
- 12 Apr 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED